03759 PHARMARON
- 10.300
- +0.430+4.36%
PHARMARON News
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
May 8 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$32.0953 million
According to documents disclosed by the Hong Kong Stock Exchange on May 9, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 8, involving an amount of HK$32.0953 million. The repurchase price per share ranged from HK$107.7 to HK$106. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 300,000 shares, accounting for 0.016% of the number of shares issued when the ordinary resolution was passed. ② $Swire Group A
Kanglong Chemical (300759.SZ): Initial repurchase of 250,000 shares involving 4.9874 million yuan
Gelonghui, May 8, 丨 Kanglong Huacheng (300759.SZ) announced that on May 8, 2024, the company used its own funds to repurchase shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 250,000 shares, accounting for 0.01% of the company's current total share capital (1,787,394,297 shares). The highest transaction price of the repurchase was 19.99 yuan/share, and the total transaction amount was 49,874.33 million yuan (excluding transaction fees).
Kanglong Chemical (03759.HK) spent 4.987 million yuan to buy back 250,000 A shares on May 8
Gelonghui, May 8, 丨 Kanglong Chemical (03759.HK) announced that it spent 4.987 million yuan to buy back 250,000 A-shares on May 8, 2024.
Kanglong Chemical (03759.HK) spent 4.9874 million yuan to buy back 250,000 A shares on May 8
Kanglong Chemical (03759.HK) announced that on May 8, 2024, the company spent 4.9874 million yuan to repurchase 250,000 A shares at a repurchase price of HK$19.92-19.99 per share.
Kanglong Chemical (03759) spent 4.9874 million yuan to buy back 250,000 A shares on May 8
Kanglong Chemical (03759) announced that on May 8, 2024, the company spent 4.9874 million yuan to return...
Express News | Kanglong Chemical: No share repurchases have been made as of the end of April
Kanglong Chemical (300759.SZ): The company did not repurchase shares
Gelonghui, May 7, 丨 Kanglong Chemical (300759.SZ) announced that during the period from April 26, 2024 to April 30, 2024 (a total of three trading days), the company did not repurchase shares.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Changes in Hong Kong stocks | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Kanglong Chemical (300759): Short-term 24Q1 performance under pressure, order trends are good, and recovery is expected
The company released its 2024 quarterly report: 2024Q1 achieved operating income of 2,671 million yuan (yoy -2.0%) and net profit to mother of 231 million yuan (yoy -33.8%), adjusted non-IF
PHARMARON To Go Ex-Dividend On June 27th, 2024 With 0.22051 HKD Dividend Per Share
May 2nd - $PHARMARON(03759.HK)$ is trading ex-dividend on June 27th, 2024. Shareholders of record on June 28th, 2024 will receive 0.22051 HKD dividend per share. The ex-dividend date is June 27th,
Pharmaron Beijing's Profit Rises 17% in 2023
Pharmaron Beijing (HKG:3759, SHE:300759) recorded a 17% rise in attributable profit for 2023 to 1.6 billion yuan from 1.37 billion yuan in 2022, according to the company's annual report. The drugmaker
Kanglong Chemical (03759) plans to repurchase 200 million to 300 million yuan of A-shares
According to the Zhitong Finance App, Kang Long Huacheng (03759) announced that since the closing price of the company's A shares fell by more than 20% in 20 consecutive trading days as of April 19, 2024, necessary to protect the company's value and shareholders' rights and effectively promote the implementation of the “Double Improvement of Quality and Return” action plan, the company plans to use its own funds to repurchase some of the company's RMB common stock A shares through centralized bidding transactions. The total amount of capital for this repurchase is not less than RMB 200 million and no more than RMB 300 million (all inclusive), and the maximum repurchase price does not exceed
2023年度報告
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
04:14 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Kanglong Chemical (300759): Signed a new rapid growth integrated platform showing resilience
Event: The company achieved operating income of 11.538 billion yuan (+12.4%) and net profit of 1.01 billion yuan (+16.5%) to mother in 2023. 2024Q1 achieved operating revenue of 2,671 billion yuan (-
Kanglong Chemical (300759) Company Information Update Report: 2024Q1 performance is under phased pressure, new business promotion opens up room for growth
Revenue growth was steady, and new customer expansion contributed to performance growth in 2024Q1. The company achieved revenue of 2,671 billion yuan, a year-on-year decrease of 1.95%; realized net profit to mother of 231 million yuan, a year-on-year decrease of 33.80%; Non-I
Analysis
Price Target
No Data
